Patent ID: 8791135

Claim:
A method for treating a patient infected with a human immunodeficiency virus or in need of relief from a human immunosuppressive virus infection comprising administering a therapeutically effective amount of a composition comprising a compound of the formula or a pharmaceutically acceptable salt thereof; wherein R is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl, each of which is optionally substituted; X 2 is —C(O)— or —CH 2 — and X 3 is —C(O)—; Q 1 is optionally substituted 1,3-phenylene; X 1A is a bond, —N(R 17 )—, —S(O) q —, or optionally substituted alkylene; and R 1A is —S(O) 2 R 14 , —C(O)R 12 , —N(R 8 )R 9 , alkyl, cycloalkyl, cycloalkyl-alkyl, heterocycloalkyl, heterocycloalkyl-alkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl, each of which is optionally substituted, or R 1A and X 1A together with the attached nitrogen form an optionally substituted heterocycle; X 4 is —C(O)— or —S(O) 2 —, and R 3 is C 3 -C 10 alkyl or cycloalkyl; X 5 is optionally substituted alkylene; R 2 is hydrogen; R 4 and R 5 are each independently selected from the group consisting of aryl and heteroaryl, each of which is optionally substituted; q is independently 0, 1, or 2 in each instance; R 20 is hydrogen; R 8 is in each instance independently selected from the group consisting of hydrogen, —C(O)R 13 , —S(O) 2 R 14 , alkyl, cycloalkyl, cycloalkyl-alkyl, heterocycloalkyl, heterocycloalkyl-alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, each of which is optionally substituted; R 9 is in each instance independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, heterocycloalkyl, heterocycloalkyl-alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, each of which is optionally substituted; R 12 and R 13 are each independently selected from the group consisting of hydrogen, —OR 19 , —N(R 18 )R 19 , alkyl, cycloalkyl, cycloalkyl-alkyl, heterocycloalkyl, heterocycloalkyl-alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, each of which is optionally substituted; R 14 is in each instance independently selected from the group consisting of hydrogen, —N(R 18 )R 19 , alkyl, cycloalkyl, cycloalkyl-alkyl, heterocycloalkyl, heterocycloalkyl-alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, each of which is optionally substituted; and R 17 , R 18 , and R 19 are in each instance independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, heterocycloalkyl, heterocycloalkyl-alkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, each of which is optionally substituted.